[{"orgOrder":0,"company":"Medigen Vaccine Biologics","sponsor":"Dynavax Technologies","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"5QB0T2IUN0","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Medigen Vaccine Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Medigen Vaccine Biologics \/ Dynavax Technologies Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Medigen Vaccine Biologics \/ Dynavax Technologies Corporation"},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"GL Ventures","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Series C Financing","leadProduct":"5QB0T2IUN0","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Clover Biopharmaceuticals","amount2":0.23000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.23000000000000001,"dosageForm":"Intramuscular Injection","sponsorNew":"Clover Biopharmaceuticals \/ GL Ventures","highestDevelopmentStatusID":"10","companyTruncated":"Clover Biopharmaceuticals \/ GL Ventures"},{"orgOrder":0,"company":"Dynavax Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"Aluminium hydroxide","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Dynavax Technologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Dynavax Technologies \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Dynavax Technologies \/ Not Applicable"},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"5QB0T2IUN0","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Clover Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Clover Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Clover Biopharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"Aluminium hydroxide","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ Not Applicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"Aluminium hydroxide","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ Not Applicable"},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Gavi","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"5QB0T2IUN0","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Clover Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Clover Biopharmaceuticals \/ Gavi","highestDevelopmentStatusID":"9","companyTruncated":"Clover Biopharmaceuticals \/ Gavi"},{"orgOrder":0,"company":"Dynavax Technologies","sponsor":"Clover Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"5QB0T2IUN0","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Dynavax Technologies","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Dynavax Technologies \/ Clover","highestDevelopmentStatusID":"9","companyTruncated":"Dynavax Technologies \/ Clover"},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"5QB0T2IUN0","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Clover Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Clover Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Clover Biopharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"The International Vaccine Institute","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"Aluminum Hydroxide","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Bharat Biotech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bharat Biotech \/ International Vaccine Institute","highestDevelopmentStatusID":"9","companyTruncated":"Bharat Biotech \/ International Vaccine Institute"},{"orgOrder":0,"company":"Valneva","sponsor":"Dynavax Technologies","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Termination","leadProduct":"Aluminium hydroxide","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Dynavax","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ Dynavax"},{"orgOrder":0,"company":"Valneva","sponsor":"UK Government","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Termination","leadProduct":"Aluminium hydroxide","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ UK Government","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ UK Government"},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"Aluminium hydroxide","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ Not Applicable"},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"5QB0T2IUN0","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Clover Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Clover Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Clover Biopharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"Aluminium Hydroxide","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ Not Applicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"Aluminium Hydroxide","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ Not Applicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Goldman Sachs & Co. LLC","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Public Offering","leadProduct":"Aluminium hydroxide","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0.10000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.10000000000000001,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Goldman Sachs & Co. LLC","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ Goldman Sachs & Co. LLC"},{"orgOrder":0,"company":"Valneva","sponsor":"European Commission","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"Aluminium Hydroxide","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ European Commission","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ European Commission"},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"Aluminium hydroxide","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ Not Applicable"},{"orgOrder":0,"company":"Valneva","sponsor":"European Commission","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"Aluminium Hydroxide","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ European Commission","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ European Commission"},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"IDOR","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"Aluminum Hydroxide","moa":"SARS-CoV-2 S-trimer","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Clover Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Clover Biopharmaceuticals \/ IDOR","highestDevelopmentStatusID":"12","companyTruncated":"Clover Biopharmaceuticals \/ IDOR"},{"orgOrder":0,"company":"Valneva","sponsor":"Kingdom of Bahrain","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"Aluminium hydroxide","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Kingdom of Bahrain","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ Kingdom of Bahrain"},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"Aluminium hydroxide","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ Not Applicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Aluminium hydroxide","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ Not Applicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Aluminium Hydroxide","moa":"SARS-CoV-2 virus spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ Not Applicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Aluminium Hydroxide","moa":"SARS-CoV-2 virus spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ Not Applicable"},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Aluminium hydroxide","moa":"SARS-CoV-2 S-trimer","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Clover Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Clover Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Clover Biopharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Aluminium Hydroxide","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ Not Applicable"},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Aluminum Hydroxide","moa":"SARS-CoV-2 S-trimer","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Clover Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Clover Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Clover Biopharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Scottish Enterprise","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"Aluminium Hydroxide","moa":"SARS-CoV-2 virus spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0.029999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.029999999999999999,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Scottish Enterprise","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ Scottish Enterprise"},{"orgOrder":0,"company":"Albumedix","sponsor":"Valneva","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2022","type":"Expanded Collaboration","leadProduct":"Aluminium Hydroxide","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Albumedix","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Albumedix \/ Valneva","highestDevelopmentStatusID":"12","companyTruncated":"Albumedix \/ Valneva"},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Aluminium Hydroxide","moa":"SARS-CoV-2 virus spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ Not Applicable"},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Aluminum Hydroxide","moa":"SARS-CoV-2 S-trimer","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Clover Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Clover Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Clover Biopharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Aluminium hydroxide","moa":"SARS-CoV-2 S-trimer","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Clover Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Clover Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Clover Biopharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Deerfield Management Company","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Financing","leadProduct":"Aluminium hydroxide","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Deerfield Management Company","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ Deerfield Management Company"},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Aluminium Hydroxide","moa":"SARS-CoV-2 virus spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ Not Applicable"},{"orgOrder":0,"company":"Valneva","sponsor":"European Commission","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Termination","leadProduct":"Aluminium Hydroxide","moa":"SARS-CoV-2 virus spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Valneva \/ European Commission","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ European Commission"},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Aluminium Hydroxide","moa":"SARS-CoV-2 virus spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ Not Applicable"},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Aluminum Hydroxide","moa":"SARS-CoV-2 S-trimer","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Clover Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Clover Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Clover Biopharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Aluminium Hydroxide","moa":"SARS-CoV-2 virus spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ Not Applicable"},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Aluminium hydroxide","moa":"SARS-CoV-2 S-trimer","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Clover Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Clover Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Clover Biopharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Aluminium Hydroxide","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable, Suspension","sponsorNew":"Emergent BioSolutions \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Emergent BioSolutions \/ Not Applicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Aluminium Hydroxide","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ Not Applicable"},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Aluminium hydroxide","moa":"SARS-CoV-2 S-trimer","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Clover Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Clover Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Clover Biopharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Aluminium Hydroxide","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ Not Applicable"},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Aluminium Hydroxide","moa":"SARS-CoV-2 S-trimer","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Clover Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Clover Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Clover Biopharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Aluminium Hydroxide","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ Not Applicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Aluminium Hydroxide","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ Not Applicable"},{"orgOrder":0,"company":"IDT Biologika GmbH","sponsor":"Valneva","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Termination","leadProduct":"Aluminium Hydroxide","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"IDT Biologika GmbH","amount2":0.040000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.040000000000000001,"dosageForm":"Injection","sponsorNew":"IDT Biologika GmbH \/ Valneva","highestDevelopmentStatusID":"12","companyTruncated":"IDT Biologika GmbH \/ Valneva"},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Aluminium Hydroxide","moa":"SARS-CoV-2 S-trimer","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Clover Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Clover Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Clover Biopharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Aluminium Hydroxide","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable, Suspension","sponsorNew":"Emergent BioSolutions \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Emergent BioSolutions \/ Not Applicable"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"CDMRP","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"Alhydrogel","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Emergent BioSolutions","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"Emergent BioSolutions \/ CDMRP","highestDevelopmentStatusID":"10","companyTruncated":"Emergent BioSolutions \/ CDMRP"},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Aluminium Hydroxide","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ Not Applicable"},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"Aluminium Hydroxide","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Clover Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Clover Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Clover Biopharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"Aluminium Hydroxide","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Clover Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Clover Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Clover Biopharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"ADvantage Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Aluminium Hydroxide","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"ADvantage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ADvantage Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ADvantage Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"ADvantage Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Aluminium Hydroxide","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"ADvantage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ADvantage Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ADvantage Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"ADvantage Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Aluminium Hydroxide","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"ADvantage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ADvantage Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ADvantage Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Ankyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Aluminum Hydroxide","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ankyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ankyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ankyra Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"ADvantage Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Aluminium Hydroxide","moa":"","graph1":"Technology","graph2":"Approved","graph3":"ADvantage Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"ADvantage Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ADvantage Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Ankyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Aluminum Hydroxide","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Ankyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Ankyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ankyra Therapeutics \/ Not Applicable"}]
Find Clinical Drug Pipeline Developments & Deals for Aluminium Hydroxide
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
